CERC-406

A "first-in-class," oral adjunctive medication for patients with residual cognitive impairment symptoms

CERC-406

Targeting Residual Cognitive Impairment Symptoms in MDD

CERC-406 is a small molecule, selective catechol-O-methyltransferase, or COMT, inhibitor that we anticipate developing as a "first-in-class," oral adjunctive medication for patients with residual cognitive impairment symptoms suffering from MDD.

Attributes
of CERC-406

  • Orally active, centrally penetrant
  • MB-COMT preferring targeting PFC dopamine deficits
  • Potentially more effective in Val homozygote population

About Cognition

Cognitive dysfunction is an important mediator of disability in MDD

Several publications, including the 2014 article by Lam et al. titled Cognitive Dysfunction in MDD: Effects on Psychosocial Functions and Implications for Treatment published in the Canadian Journal of Psychiatry, indicate that cognitive dysfunction is an important mediator of disability in MDD. Self-perceived cognitive impairment has always been recognized as a clinical manifestation of MDD. Cognitive domains that are measurably impaired in MDD include attention, memory, processing speed and executive function. As discussed by Lam et al., up to 50% of patients with MDD exhibit measureable cognitive deficits. CERC-406 is our preclinical lead candidate from our COMTi platform, which is comprised of novel molecules with selectivity for membrane bound COMT, the domminant form of COMT within the CNS.

Mechanism of Action

Selective, brain penetrant COMT inhibitor

Our COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, the dominant form of COMT found within the central nervous system. We believe these potent COMT inhibitors may selectively increase dopamine levels in the PFC, thereby improving executive function. We believe our selective COMT inhibitors may avoid off‐target toxicity and side effects seen with the previous generation of COMT inhibitors, such as liver toxicity observed in tolcapone and diarrhea observed with entacapone and tolcapone.